Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Physiomics Fundamentals

Company Name Physiomics Last Updated 21 Oct 2020
Industry Health Care Sector Medical Equipment
Shares in Issue (m) 97.33 Market Cap (£m) 6.47
PE Ratio -73.89 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -0.09 EPS Growth (%) 35.71
PEG -2.07 DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing -63.30 Gross Gearing 9.12
Asset Equity Ratio 1.10 Cash Equity Ratio 79.70
Quick Ratio 10.84 Current Ratio 10.84
Price To Book Value 4.90 ROCE -9.85

Physiomics Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Physiomics Company Financials

Assets (£m) 2020 2019 2018
Tangible Assets 0 0 0
Intangible Assets 0 0 0
Investments 0 0 0
Total Fixed Assets 0 0 0
Stocks 0 0 0
Debtors 0 0 0
Cash & Equivalents 1 0 1
Other Assets 0 0 0
Total Assets 1 1 1
Liabilities (£m) 2020 2019 2018
Creditors within 1 year 0 0 0
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 0 0 0
Net assets 1 1 1
Equity (£m) 2020 2019 2018
Called up share capital 1 1 1
Share Premium 6 5 5
Profit / Loss -0 -0 -0
Other Equity 0 0 0
Preference & Minorities 0 0 0
Total Capital Employed 1 1 1
Ratios 2020 2019 2018
Debt Ratio 0.00 0.00 0.00
Debt-to-Equity 0.00 0.00 0.00
Net Gearing -63.30 -45.97 -54.28
Gross Gearing 9.12 12.39 15.65
Assets / Equity 1.10 1.14 1.19
Cash / Equity 79.70 66.61 82.90
EPS -0.09 -0.14 -0.31
Cash Flow (£m) 2020 2019 2018
Cash from operating activities -0 -0 -0
Cashflow before financing -0 -0 -0
Increase in Cash 1 -0 0
Income (£m) 2020 2019 2018
Turnover 1 1 1
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -0 -0 -0
Pre-Tax profit -0 -0 -0
Profit / Loss for the year 1 1 1

Physiomics Company Background

Sector Medical Equipment
Activities Physiomics plc is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly. Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Latest Interim Date 03 Mar 2020
Latest Fiscal Year End Date 30 Sep 2020

Physiomics Directors

Appointed Director Position
2016-04-18 Dr James Simon Millen Chief Executive Officer
2007-05-01 Dr Christophe David Chassagnole Chief Operating Officer
2004-09-24 Dr Paul Bernard Harper Non-Executive Chairman

Physiomics Contact Details

Company Name Physiomics
Company Address The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford OX4 4GA.
Company Telephone 01865 784 980
Company Website http://www.physiomics-plc.com/

Physiomics Advisors

Auditor Name n/a
Auditor Address n/a
Auditor Website n/a
Auditor Telephone n/a
Registrar Name n/a
Registrar Address n/a
Registrar Website n/a
Registrar Telephone n/a
Broker Name n/a
Broker Address n/a
Broker Website n/a
Broker Telephone n/a
Adviser Name n/a
Adviser Address n/a
Adviser Website n/a
Adviser Telephone n/a
Solicitor Name n/a
Solicitor Address n/a
Solicitor Website n/a
Solicitor Telephone n/a
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a